Noninvasive fetal RhD genotyping

Transfusion and Apheresis Science

Volumn 50, Issue 2, 2014, Pages 154-162

  Clausen, Frederik Banch ^a   Damkjær, Merete Berthu ^b   Dziegiel, Morten Hanefeld ^a,b  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RHESUS D ANTIBODY; RHESUS D ANTIGEN; BLOOD GROUP RHESUS SYSTEM; RHO(D) ANTIGEN;

ALLOIMMUNIZATION; CELL FREE SYSTEM; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; EXON; GENOTYPING TECHNIQUE; GESTATIONAL AGE; HUMAN; IMMUNIZATION; MATERNAL PLASMA; NEWBORN HEMOLYTIC DISEASE; NON INVASIVE PROCEDURE; POLYMERASE CHAIN REACTION; POSTNATAL CARE; PREGNANT WOMAN; PRENATAL CARE; PRENATAL DIAGNOSIS; REVIEW; RHESUS INCOMPATIBILITY; BLOOD; BLOOD GROUP RHESUS SYSTEM; BLOOD GROUP TYPING; ERYTHROBLASTOSIS, FETAL; FEMALE; GENETICS; PREGNANCY; PROCEDURES;

BLOOD GROUPING AND CROSSMATCHING; DNA; ERYTHROBLASTOSIS, FETAL; FEMALE; GENOTYPING TECHNIQUES; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; RH-HR BLOOD-GROUP SYSTEM;

EID: 84900509099     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2014.02.008     Document Type: Review

References (113)

1. Urbaniak S.J., Greiss M.A. RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000, 14:44-61.
2. Tiblad E., Westgren M., Pasupathy D., Karlsson A., Wikman A.T. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies. Acta Obstet Gynecol Scand 2013, 92:1079-1085.
3. Mari G., Deter R.L., Carpenter R.L., Rahman F., Zimmerman R., Moise K.J., et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000, 342:9-14.
4. Daniels G. The molecular genetics of blood group polymorphism. Hum Genet 2009, 126:729-742.
5. Urbaniak S.J. The scientific basis of antenatal prophylaxis. BJOG 1998, 105(suppl. 18):11-18.
6. Bowman J.M., Crown B., Lewis M., Pollock J.M. Rh isoimmunization during pregnancy: antenatal prophylaxis. CMA J 1978, 118:623-627.
7. van der Schoot C.E., Hahn S., Chitty L.S. Non-invasive prenatal diagnosis and determination of fetal Rh status. Sem Fetal Neonatal Med 2008, 13:63-68.
8. Clausen F.B., Christiansen M., Steffensen R., Jørgensen S., Nielsen C., Jakobsen M.A., et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D-pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012, 52:752-758.
9. Dziegiel M.H. Noninvasive prenatal screening for RHD: the 1st national antenatal directed anti-D prophylaxis program - the Danish model or a guide to robust prediction of need of anti-D. ISBT Sci Ser 2012, 7:160-163.
10. de Haas M., van der Ploeg C.P.B., Scheffer P.G., Verlinden D.A., Hirschberg H., Abbink F., et al. A nation-wide fetal RHD screening programme for targeted antenatal and postnatal anti-D. ISBT Sci Ser 2012, 7:164-167.
11. Minon J.-M., Gerard C., Senterre J.-M., Schaaps J.-P., Foidart J.-M. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion 2008, 48:373-381.
12. Wikman A.T., Tiblad E., Karlsson A., Olsson M.L., Westgren M., et al. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012, 120:227-234.
13. Daniels G., Finning K., Martin P., Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009, 29:101-107.
14. Maddocks D.G., Alberry M.S., Attilakos G., Madgett T.E., Choi K., Soothill P.W., et al. The SAFE project: towards non-invasive prenatal diagnosis. Biochem Soc Trans 2009, 37:460-465.
15. Scheffer P.G., de Haas M., van der Schoot C.E. The controversy about controls for fetal blood group genotyping by cell-free fetal DNA in maternal plasma. Curr Opin Hematol 2011, 18:467-473.
16. Daniels G., van der Schoot C.E., Olsson M.L. Report of the fourth International Workshop on molecular blood group genotyping. Vox Sang 2011, 101:327-332.
17. Maron J.L., Bianchi D.W. Prenatal diagnosis using cell-free nucleic acids in maternal body fluids: a decade of progress. Am J Med Genet C: Semin Med Genet 2007, 145C:5-17.
18. Chiu R.W.K., Lo Y.M.D. Clinical applications of maternal plasma fetal DNA analysis: translating the fruits of 15 years of research. Clin Chem Lab Med 2013, 51:197-204.
19. Lo Y.M.D., Corbetta N., Chamberlain P.F., Rai V., Sargent I.L., Redman C.W.G., et al. Presence of fetal DNA in maternal plasma and serum. The Lancet 1997, 350:485-487.
20. Lo Y.M.D., Hjelm N.M., Fidler C., Sargent I.L., Murphy M.F., Chamberlain P.F., et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998, 339:1734-1738.
21. Lo Y.M., Tein M.S., Lau T.K., Haines C.J., Leung T.N., Poon P.M., et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998, 62:768-775.
22. Faas B.H.W., Beuling E.A., Christiaens G.C.M.L., Von Dem Borne A.E.G., van der Schoot C.E. Detection of fetal RHD-specific sequences in maternal plasma. The Lancet 1998, 352:1196.
23. Alberry M., Maddocks D., Jones M., Hadi M.A., Abdel-Fattah S., Avent N., et al. Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast. Prenat Diagn 2007, 27:415-418.
24. Masuzaki H., Miura K., Yoshimura K.-i., Niikawa N., Ishimaru T. Detection of cell free placental DNA in maternal plasma: direct evidence from three cases of confined placental mosaicism. J Med Genet 2004, 41:289-292.
25. Flori E., Doray B., Gautier E., Kohler M., Ernault P., Flori J., et al. Circulating cell-free fetal DNA in maternal serum appears to originate from cyto- and syncytio-trophoblastic cells. Hum Reprod 2004, 19:723-724.
26. Huppertz B., Kadyrov M., Kingdom J.C.P. Apoptosis and its role in the trophoblast. Am J Obstet Gynecol 2006, 195:29-39.
27. Chan K.C., Zhang J., Hui A.B., Wong N., Lau T.K., Leung T.N., et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 2004, 50:88-92.
28. Lo Y.M., Chan K.C., Sun H., Chen E.Z., Jiang P., Lun F.M., et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010, 2. 61ra91.
29. Finning K.M., Martin P.G., Soothill P.W., Avent N.D. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002, 42:1079-1085.
30. Birch L., English C.A., O'Donoghue K., Barigye O., Fisk N.M., Keer J.T. Accurate and robust quantification of circulating fetal and total DNA in maternal plasma from 5 to 41 weeks of gestation. Clin Chem 2005, 51:312-320.
31. Galbiati S., Smid M., Gambini D., Ferrari A., Restagno G., Viora E., et al. Fetal DNA detection in maternal plasma throughout gestation. Hum Genet 2005, 117:243-248.
32. Yu S.C., Lee S.W., Jiang P., Leung T.Y., Chan K.C., Chiu R.W., et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin Chem 2013, 59:1228-1237.
33. Clausen F.B., Jakobsen T.R., Rieneck K., Krog G.R., Nielsen L.K., Tabor A., et al. Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD. PLoS ONE 2013, 8:e76990.
34. Hahn S., Zhong X.Y., Bürk M.R., Troeger C., Kang A., Holzgreve W. Both maternal and fetal cell-free DNA in plasma fluctuate. Ann NY Acad Sci 2001, 945:141-144.
35. Dovč-Drnovšek T., Klemenc P., Toplak N., Blejec T., Bricl I., Rožman P. Reliable determination of fetal RhD status by RHD genotyping from maternal plasma. Transfus Med Hemother 2013, 40:37-43.
36. Illanes S., Denbow M., Kailasam C., Finning K., Soothill P.W. Early detection of cell-free fetal DNA in maternal plasma. Early Hum Dev 2007, 83:563-566.
37. Rijnders R.J., Van Der Luijt R.B., Peters E.D., Goeree J.K., Van Der Schoot C.E., Ploos Van Amstel J.K., et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat Diagn 2003, 23:1042-1044.
38. Devaney S.A., Palomaki G.E., Scott J.A., Bianchi D.W. Noninvasive fetal sex determination using cell-free fetal DNA. A systematic review and meta-analysis. JAMA 2011, 306:627-636.
39. Daniels G., Finning K., Wade A., Massey E., Soothill P., Martin W.L., et al. Implementation of routine of fetal RHD typing in all RHD-negative pregnant women: timing, costs, and efficiency. Vox Sang 2012, 103(suppl. 1):34.
40. Zhang J., Fidler C., Murphy M.F., Chamberlain P.F., Sargent I.L., Redman C.W., et al. Determination of fetal RhD status by maternal plasma DNA analysis. Ann NY Acad Sci 2000, 906:153-155.
41. Randen I., Hauge R., Kjeldsen-Kragh J., Fagerhol M.K. Prenatal genotyping of RHD and SRY using maternal blood. Vox Sang 2003, 85:300-306.
42. Rijnders R.J.P., Christiaens G.C.M.L., Bossers B., van der Smagt J.J., van der Schoot E., de Haas M. Clinical applications of cell-free fetal DNA from maternal plasma. Am College Obstet Gynecol 2004, 103:157-164.
43. Rouillac-Le Sciellour C., Puillandre P., Gillot R., Baulard C., Métral S., Le Van Kim C., et al. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn 2004, 8:23-31.
44. Akolekar R., Finning K., Kuppusamy R., Daniels G., Nicolaides K.H. Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation. Fetal Diagn Ther 2011, 29:301-306.
45. Johnson K.L., Dukes K.A., Vidaver J., LeShane E.S., Ramirez I., Weber W.D., et al. Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. Clin Chem 2004, 50:516-521.
46. Barret A.N., Zimmermann B.G., Wang D., Holloway A., Chitty L.S. Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield. PLoS ONE 2011, 6:e25202.
47. Lui Y.Y.N., Lo Y.M.D. Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications. Clin Chem Lab Med 2002, 40:962-968.
48. El Messaoudi S., Rolet F., Mouliere F., Thierry A.R. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013, 424:222-230.
49. Lo Y.M.D., Zhang J., Leung T.N., Lau T.K., Chang A.M.Z., Hjelm M. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999, 64:218-224.
50. Angert R.M., LeShane E.S., Lo Y.M.D., Chan L.Y.S., Delli-Bovi L.C., Bianchi D.W. Fetal cell-free plasma DNA concentrations in maternal blood are stable 24 hours after collection: analysis of first- and third-trimester samples. Clin Chem 2003, 49:195-198.
51. Müller S.P., Bartels I., Stein W., Emons G., Gutensohn K., Legler T.J. Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days. Prenat Diagn 2011, 31:1300-1304.
52. Fernando M.R., Chen K., Norton S., Krzyzanowski G., Bourne D., Ryan W.L., et al. A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage. Prenat Diagn 2010, 30:418-424.
53. Wong D., Moturi S., Angkachatchai V., Mueller R., DeSantis G., Van Den Boom D., et al. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin Biochem 2013, 46:1099-1104.
54. Clausen F.B., Krog G.R., Rieneck K., Dziegiel M.H. Improvement in fetal DNA extraction from maternal plasma. Evaluation of the NucliSens Magnetic Extraction system and the QIAamp DSP Virus Kit in comparison with the QIAamp DNA Blood Mini Kit. Prenat Diagn 2007, 27:6-10.
55. Legler T.J., Liu Z., Mavrou A., Finning K., Hromadnikova I., Galbiati S., et al. Workshop report on the extraction of foetal DNA from maternal plasma. Prenat Diagn 2007, 27:824-829.
56. Repiská G., Sedláčkova T., Szemes T., Celec P., Minárik G. Selection of the optimal manual method of cell free fetal DNA isolation from maternal plasma. Clin Chem Lab Med 2012, 8:1-5.
57. Brojer E., Zupanska B., Guz K., Orzinska A., Kaliñska A. Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma. Transfusion 2005, 45:1473-1480.
58. Legler T.J., Müller S.P., Haverkamp A., Grill S., Hahn S. Prenatal RhD testing: a review of studies published from 2006 to 2008. Transfus Med Hemother 2009, 36:189-198.
59. Clausen F.B., Krog G.R., Rieneck K., Råsmark E.E.F., Dziegiel M.H. Evaluation of two real-time multiplex PCR screening assays detecting fetal RHD in plasma from RhD negative women to ascertain the requirement for antenatal RhD prophylaxis. Fetal Diagn Ther 2011, 29:155-163.
60. Grootkerk-Tax M.G.H.M., Soussan A.A., de Haas M., Maaskant-van Wijk P.A., van der Schoot C.E. Evalution of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion 2006, 46:2142-2148.
61. Koide K., Sekizawa A., Iwasaki M., Matsuoka R., Honma S., Farina A., et al. Fragmentation of cell-free fetal DNA in plasma and urine of pregnant women. Prenat Diagn 2005, 25:604-607.
62. Sikora A., Zimmermann B.G., Rusterholz C., Birri D., Kolla V., Lapaire O., et al. Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin Chem 2010, 56:136-138.
63. Lun F.M., Chiu R.W., Allen Chan K.C., Yeung Leung T., Kin Lau T., Dennis Lo Y.M. Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin Chem 2008, 54:1664-1672.
64. Grill S., Banzola I., Li Y., Rekhviashvili T., Legler T.J., Müller S.P., et al. High throughput non-invasive determination of foetal Rhesus D status using automated extraction of cell-free foetal DNA in maternal plasma and mass spectrometry. Arch Gynecol Obstet 2009, 279:533-537.
65. Tynan J.A., Angkachatchai V., Ehrich M., Paladino T., van den Boom D., Oeth P. Multiplexed analysis of circulating cell-free fetal nucleic acids for noninvasive prenatal diagnostic RHD testing. Am J Obstet Gynecol 2011, 204(251):e1-e6.
66. Moise K.J., Boring N.H., O'Shaughnessy R., Simpson L.L., Wolfe H.M., Baxter J.K., et al. Circulating cell-free fetal DNA for the detection of RHD status and sex using reflex fetal identifiers. Prenat Diagn 2013, 33:95-101.
67. Rieneck K., Bak M., Jønson L., Clausen F.B., Krog G.R., Tommerup N., et al. Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma. Transfusion 2013, 10.1111/trf.12172.
68. Daniels G., Finning K., Martin P., Soothill P. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang 2004, 87:225-232.
69. Avent N.D., Madgett T.E., Lee Z.E., Head D.J., Maddocks D.G., Skinner L.H. Molecular biology of Rh proteins and relevance to molecular medicine. Exp Rev Mol Med 2006, 8:1-20.
70. Wagner F.F., Flegel W.A. Review: the molecular basis of the Rh blood group phenotypes. Immunohematology 2004, 20:23-36.
71. Westhoff C.M. The structure and function of the Rh antigen complex. Semin Hematol 2007, 44:42-50.
72. Daniels G., Green C., Smart E. Differences between RhD-negative Africans and RhD-negative Europeans. The Lancet 1997, 350:862-863.
73. Singleton B.K., Green C.A., Avent N.D., Martin P.G., Smart E., Daka A., et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype. Blood 2000, 95:12-18.
74. Daniels G. Variants of RhD - current testing and clinical consequences. Br J Haematol 2013, 161:461-470.
75. Wagner F.F., Gassner C., Müller T.H., Schönitzer D., Schunter F., Flegel W.A. Molecular basis of weak D phenotypes. Blood 1999, 93:385-393.
76. Flegel W.A., von Zabern I., Wagner F. Six years' experience performing RHD genotyping to confirm D - red blood cell units in Germany for preventing anti-D immunizations. Transfusion 2009, 49:465-471.
77. Flegel W.A. Molecular genetics of RH and its clinical application. Transfus Clin Biol 2006, 13:4-12.
78. Wagner F.F. RHD PCR of D-negative blood donors. Transfus Med Hemother 2013, 40:172-181.
79. Flegel W.A., Denomme G.A., Yazer M.H. On the complexity of D antigen typing: a handy decision tree in the age of molecular blood group diagnostics. J Obstet Gynaecol Can 2007, 29:746-752.
80. Geifman-Holtzman O., Grotegut C.A., Gaughan J.P. Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood - a meta-analysis. Am J Obstet Gynecol 2006, 195:1163-1173.
81. Kolialexi A., Tounta G., Mavrou A. Noninvasive fetal RhD genotyping from maternal blood. Expert Rev Mol Diagn 2010, 10:285-296.
82. van der Schoot C.E., Tax G.H., Rijnders R.J., de Haas M., Christiaens G.C. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev 2003, 17:31-44.
83. Daniels G., Finning K., Martin P., Summers J. Fetal blood group genotyping: present and future. Ann NY Acad Sci 2006, 1075:88-95.
84. Hyland C.A., Gardener G.J., Davies H., Ahvenainen M., Flower R.L., Irwin D., et al. Evaluation of non-invasive prenatal RHD genotyping of the fetus. Med J Aust 2009, 191:21-25.
85. Wang X.D., Wang B.L., Ye S.L., Liao Y.Q., Wang L.F., He Z.M. Non-invasive foetal RHD genotyping via real-time PCR of foetal DNA from Chinese RhD-negative maternal plasma. Eur J Clin Invest 2009, 39:607-617.
86. Macher H.C., Noguerol P., Medrano-Campillo P., Garrido-Márquez M.R., Rubio-Calvo A., Carmona-González M., et al. Standardization non-invasive fetal RHD and SRY determination into clinical routine using a new multiplex RT-PCR assay for fetal cell-free DNA in pregnant women plasma: results in clinical benefits and cost saving. Clin Chim Acta 2012, 413:490-494.
87. Grande M., Ordoñez E., Cirigliano V., Cid J., Grau E., Pericot A., et al. Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population. Prenat Diagn 2013, 33:173-178.
88. Scheffer P.G., van der Schoot C.E., Page-Christiaens G.C., de Haas M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011, 118:1340-1348.
89. Cardo L., García B.P., Alvarez F.V. Non-invasive fetal RHD genotyping in the first trimester of pregnancy. Clin Chem Lab Med 2010, 48:1121-1126.
90. Zhou L., Thorson J.A., Nugent C., Davenport R.D., Butch S.H., Judd W.J. Noninvasive prenatal RHD genotyping by real-time polymerase chain reaction using plasma from D-negative pregnant women. Am J Obstet Gynecol 2005, 193:1966-1971.
91. Doescher A., Petershofen E.K., Wagner F.F., Schunter M., Müller T.H. Evaluation of single-nucleotide polymorphisms as internal controls in prenatal diagnosis of fetal blood groups. Transfusion 2013, 53:353-362.
92. Tynan J.A., Mahboubi P., Cagasan L.L., van den Boom D., Ehrich M., Oeth P. Restriction enzyme-mediated enhanced detection of circulating cell-free fetal DNA in maternal plasma. J Mol Diagn 2011, 13:382-389.
93. Chan K.C., Ding C., Gerovassili A., Yeung S.W., Chiu R.W., Leung T.N., et al. Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006, 52:2211-2218.
94. Li Y., Kazzaz J.A., Kellner L.H., Brown S.A. Incorporation of fetal DNA detection assay in a noninvasive RhD diagnostic test. Prenat Diagn 2010, 30:1010-1012.
95. Zejskova L., Jancuskova T., Kotlabova K., Doucha J., Hromadnikova I. Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma - next step toward reliable non-invasive prenatal diagnostics. Exp Mol Pathol 2010, 89:241-247.
96. Kolialexi A., Tounta G., Apostolou P., Vrettou C., Papantoniou N., Kanavakis E., et al. Early non-invasive detection of fetal Y chromosome sequences in maternal plasma using multiplex PCR. Eur J Obstet Gynecol Reprod Biol 2012, 161:34-37.
97. White H.E., Dent C.L., Hall V.J., Crolla J.A., Chitty L.S. Evaluation of a novel assay for detection of the fetal marker RASSF1A: facilitating improved diagnostic reliability of noninvasive prenatal diagnosis. PLoS One 2012, 7:e45073.
98. Tsui N.B., Hyland C.A., Gardener G.J., Danon D., Fisk N.M., Millard G., et al. Noninvasive fetal RHD genotyping by microfluidics digital PCR using maternal plasma from two alloimmunized women with the variant RHD(IVS3 + 1G > A) allele. Prenat Diagn 2013, 10.1002/pd.4230.
99. van der Schoot C.E., Soussan A.A., Koelewijn J., Bonsel G., Paget-Christiaens L.G., de Haas M. Non-invasive antenatal RHD typing. Transfus Clin Biol 2006, 13:53-57.
100. Finning K., Martin P., Summers J., Massey E., Poole G., Daniels G. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008, 336:816-818.
101. Müller S.P., Bartels I., Stein W., Emons G., Gutensohn K., Köhler M., et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008, 48:2292-2301.
102. Haer-Wigman L., Veldhuisen B., Jonkers R., Lodén M., Madgett T.E., Avent N.D., et al. RHD and RHCE variant and zygosity genotyping via multiplex ligation-dependent probe amplification. Transfusion 2013, 53:1559-1574.
103. Damkjaer M.B., Perslev A., Clausen F.B., Dziegiel M.H., Jørgensen F.S. Study of compliance with a new, targeted antenatal D immunization prevention programme in Denmark. Vox Sang 2012, 103:145-149.
104. Tiblad E., Taune Wikman A., Ajne G., Blanck A., Jansson Y., Karlsson A., et al. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation - outcome of a new antenatal screening and prevention program. PLoS One 2013, 8:e70984.
105. de Haas M., van der Schoot E. Prenatal screening. ISBT Sci Ser 2013, 8:6-10.
106. Metcalfe P., Rigsby P., Tait E., Urbaniak S. An international reference reagent for the detection of RHD and SRY DNA in plasma. Vox Sang 2012, 102:243-249.
107. Szczepura A., Osipenko L., Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregn Childbirth 2011, 11:5.
108. Benachi A., Delahaye S., Leticee N., Jouannic J.M., Ville Y., Costa J.M. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study. Eur J Obstet Gynecol Reprod Biol 2012, 162:28-32.
109. Nicolaides K.H. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011, 29:183-196.
110. Finning K., Martin P., Summers J., Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 2007, 47:2126-2133.
111. Gutensohn K., Müller S.P., Thomann K., Stein W., Suren A., Körtge-Jung S., et al. Diagnostic accuracy of noninvasive polymerase chain reaction testing for the determination of fetal rhesus C, c and E status in early pregnancy. BJOG 2010, 117:722-729.
112. van der Schoot C.E., Thurik F.F., Veldhuisen B., de Haas M. Noninvasive prenatal blood group and HPA-1a genotyping: the current European experience. Transfusion 2013, 10.1111/trf.12411.
113. Kjeldsen-Kragh J., Ni H., Skogen B. Towards a prophylactic treatment of HPA-related foetal and neonatal alloimmune thrombocytopenia. Curr Opin Hematol 2012, 19:469-474.